Weight Loss Drug

Eli Lilly’s blockbuster drug Mounjaro has quickly become the market leader in the segment, thanks to its strong clinical performance and early entry advantage.

Roche to buy 89bio for up to $3.5 billion in obesity push

Roche is seeking to catch up with Novo Nordisk A/S and Eli Lilly & Co., makers of multibillion-dollar blockbusters Wegovy and Zepbound

India bulk drug makers start preparing for Ozempic patent expiry

Drugmakers in India — the world’s largest supplier of non-patented medicines — aim to tap what could be a $94 billion global opportunity by 2035

Chart of the Day: Weight loss drugs are making their presence felt in Indian pharma market

Sales of weight loss drug Mounjaro doubled in August

Lilly to launch Mounjaro pen in India to compete with Novo's weight-loss drug Wegovy

Lilly started selling Mounjaro in India in late March for diabetes and obesity, and it was so far available only in 2.5 mg and 5 mg vials

Novo Nordisk launches blockbuster weight loss drug Wegovy in India

The drug will follow a four-week cycle for dosage, starting with the smallest dose of 0.25 mg per week for four weeks, followed by a gradual increase in dosage.

Mounjaro side effects revealed: Decreased appetite, mild nausea and more

Mounjaro, the new weight loss drug, is gaining popularity in India for its rapid results. Patients report better appetite control, blood sugar management, and significant weight loss.

Is Ozempic beneficial for you? Nutritionist explains how it can diminish your natural glow

Is Ozempic good for you? A nutritionist advises caution while using weight loss drugs. Here's what to keep in mind

Eli Lilly may manufacture weight-loss drug Mounjaro in India in future, says CEO David Ricks

Mounjaro is a very big opportunity, given that a significant number of people have diabetes in India, says the CEO

Move over Ozempic. Mounjaro is the new weight loss drug in the market

Weight loss and diabetes: As research continues, Mounjaro may redefine medical weight loss strategies, but its ethical implications and long-term effects must be carefully monitored.

Eli Lilly plans launch of weight-loss drug in emerging markets by 2026, CFO says

In February last year, Lilly CEO David Ricks told Reuters that it expects to launch Mounjaro, in India as early as next year.

Ozempic: A miracle weight-loss drug or dangerous trend? We examine

With rumours circulating that Selena Gomez and other celebrities have used Ozempic, we reached out to experts to understand its benefits and whether it’s a one-stop solution for weight loss and diabetes management.

Weight loss drug opportunity is increasingly coming into focus for Indian pharma

Companies are preparing to launch the generic version of Semaglutide in India next year

Novo Nordisk falls most on record after new weight drug disappoints

The shot helped patients lose an average of 20.4% of their weight over 68 weeks, short of the 25% weight loss that Novo had predicted for its next-generation product, which analysts had expected to launch in 2026.

Morepen Labs forays into obesity market with nutrition products and health-tracking app

"India’s obesity market is expected to grow to $52.3 billion by 2032, reflecting the urgency to address weight management with solutions that are both safe and effective," Varun Suri, Managing Director of Dr Morepen said.

Health benefits of matcha tea: The superfood to lose weight, boost immunity, keep skin smooth

Matcha tea benefits: From fighting cancer, to aiding weight loss, enhancing mental clarity and even improving skin health when used as a face pack, the matcha tea is full of health benefits that you will be surprised to know.

Weight-Loss Drug Sales Forecast To Hit $150 Billion By 2030 | Wegovy & Zepbound Lead The Charge

Healthcare analysts project a 50% increase in annual sales for weight-loss drugs, estimating a market value of $150 billion by the early 2030s. Key players include Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, which have captured widespread interest despite limited insurance coverage. Analysts note these drugs could soon be covered by insurers due to their potential in preventing costly health emergencies. Despite 2023 shortages, increased production is underway. Shares in Lilly and Novo have surged, reflecting their growing market dominance. Discover the future of obesity treatment with 80 experimental drugs in the pipeline.

Open to market Eli Lilly’s weight loss drugs in India: Cipla CEO

Currently Cipla has the right to sell, promote and distribute two diabetes drugs of Eli Lilly in India

Biocon leads India push into weight loss drugs as patents lapse

The Bengaluru-based firm has scored an early win among its peers with the UK approval for the first generic version of liraglutide injectible, which is losing patent protection in November.

Ozempic obsession: Hollywood’s weight loss fixation; why it is in spotlight once again

Discussions and focus on health topics are rife today, a day after World Cancer Day. On that note, Ozempic, originally designed to tackle Type 2 diabetes, caused a stir as the latest weight loss craze in Tinseltown

Anti-Obesity Drug: Science Finally Lets You Lose Weight Without Diet Or Exercise

Patients with obesity issues may have found a magical drug that will keep them free from grave consequences. A drug named semaglutide suppresses appetite in its fight against obesity and is likely to cut down body weight by 20%.